Qomolangma Acquisition Corp.

$ Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000121390023038897 Filed on May 12, 2023

Income Statement

Concept	2023 Q2	2023 Q1	2022 Q1

Balance Sheet

Concept	2023 Q2	2023 Q1	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$50.00K	$170.0K	$100.0K
YoY Change	-28.57%	70.0%
Cash & Equivalents	$49.75K	$167.8K	$101.8K
Short-Term Investments
Other Short-Term Assets	$180.0K	$230.0K
YoY Change
Inventory
Prepaid Expenses	$177.1K	$233.3K
Receivables
Other Receivables
Total Short-Term Assets	$226.9K	$401.1K	$100.0K
YoY Change	224.13%	301.07%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$55.38M	$54.49M
YoY Change
Other Assets			$150.0K
YoY Change
Total Long-Term Assets	$55.38M	$54.49M	$150.0K
YoY Change	30664.08%	36223.76%
TOTAL ASSETS
Total Short-Term Assets	$226.9K	$401.1K	$100.0K
Total Long-Term Assets	$55.38M	$54.49M	$150.0K
Total Assets	$55.60M	$54.89M	$250.0K
YoY Change	22140.9%	21854.68%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable
YoY Change
Accrued Expenses	$612.6K	$560.0K	$40.00K
YoY Change	1431.38%	1300.01%
Deferred Revenue
YoY Change
Short-Term Debt	$600.0K	$360.0K	$200.0K
YoY Change	200.0%	80.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$23.97M	$1.084M	$240.0K
YoY Change	9886.89%	351.73%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$2.110M	$2.110M
YoY Change
Total Long-Term Liabilities	$2.110M	$2.110M	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$23.97M	$1.084M	$240.0K
Total Long-Term Liabilities	$2.110M	$2.110M	$0.00
Total Liabilities	$26.13M	$3.237M	$240.0K
YoY Change	10785.7%	1248.64%
SHAREHOLDERS EQUITY
Retained Earnings	-$3.399M	-$93.26K
YoY Change
Common Stock	$166.00	$166.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$3.399M	$1.019M	$13.75K
YoY Change
Total Liabilities & Shareholders Equity	$55.60M	$54.89M	$250.0K
YoY Change	22140.9%	21854.68%

Cashflow Statement

Concept	2023 Q2	2023 Q1	2022 Q1

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q4	us-gaap	Deferred Compensation Liability Classified Noncurrent DeferredCompensationLiabilityClassifiedNoncurrent	2109200	usd
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	001-41518
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	Qomolangma Acquisition Corp.
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	86-3733656
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	1178 Broadway
CY2023Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	3rd Floor
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	New York
CY2023Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	NY
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	10010
CY2023Q1	dei	City Area Code CityAreaCode	(646)
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	791-7587
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2023Q1	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	true
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	6935623	shares
CY2023Q1	us-gaap	Cash Cash	167777	usd
CY2022Q4	us-gaap	Cash Cash	196510	usd
CY2023Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	233296	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	235476	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	401073	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	431986	usd
CY2023Q1	us-gaap	Assets Held In Trust AssetsHeldInTrust	54485634	usd
CY2022Q4	us-gaap	Assets Held In Trust AssetsHeldInTrust	53958681	usd
CY2023Q1	us-gaap	Assets Assets	54886707	usd
CY2022Q4	us-gaap	Assets Assets	54390667	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	560005	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	124599	usd
CY2023Q1	qomo	Franchise Tax Payable FranchiseTaxPayable	12700	usd
CY2022Q4	qomo	Franchise Tax Payable FranchiseTaxPayable	45428	usd
CY2023Q1	us-gaap	Taxes Payable Current TaxesPayableCurrent	156416	usd
CY2022Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	46115	usd
CY2023Q1	us-gaap	Related Party Deposit Liabilities RelatedPartyDepositLiabilities	355025	usd
CY2022Q4	us-gaap	Related Party Deposit Liabilities RelatedPartyDepositLiabilities	155025	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	1084146	usd
CY2023Q1	us-gaap	Liabilities Liabilities	3236742	usd
CY2022Q4	us-gaap	Liabilities Liabilities	2516531	usd
CY2023Q1	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	16000000	shares
CY2022Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	16000000	shares
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	371167	usd
CY2023Q1	us-gaap	Deferred Tax And Other Liabilities Noncurrent DeferredTaxAndOtherLiabilitiesNoncurrent	43396	usd
CY2022Q4	us-gaap	Deferred Tax And Other Liabilities Noncurrent DeferredTaxAndOtherLiabilitiesNoncurrent	36164	usd
CY2023Q1	us-gaap	Deferred Compensation Liability Classified Noncurrent DeferredCompensationLiabilityClassifiedNoncurrent	2109200	usd
CY2023Q1	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	5273000	shares
CY2022Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	5273000	shares
CY2023Q1	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	5273000	shares
CY2022Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	5273000	shares
CY2023Q1	qomo	Common Stock Value1 CommonStockValue1	50630974	usd
CY2022Q4	qomo	Common Stock Value1 CommonStockValue1	46828833	usd
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	16000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	16000000	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1662623	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1662623	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1662623	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1662623	shares
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	166	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	166	usd
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1112080	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	4914221	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-93255	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	130916	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	1018991	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	5045303	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	54886707	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	54390667	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	666320	usd
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1682	usd
CY2023Q1	us-gaap	Franchisor Costs FranchisorCosts	12700	usd
CY2022Q1	us-gaap	Franchisor Costs FranchisorCosts	5636	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-679020	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-7318	usd
CY2023Q1	us-gaap	Interest Income Securities Other Us Government InterestIncomeSecuritiesOtherUSGovernment	572382	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-106638	usd
CY2022Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-7318	usd
CY2023Q1	qomo	Deferred Tax Provision DeferredTaxProvision	117533	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-224171	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-7318	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	5045303	usd
CY2023Q1	us-gaap	Temporary Equity Accretion To Redemption Value TemporaryEquityAccretionToRedemptionValue	3802141	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-224171	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	1018991	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	21065	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-7318	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	13747	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-224171	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-7318	usd
CY2023Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	572382	usd
CY2023Q1	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	7232	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-2180	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	435406	usd
CY2022Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-25000	usd
CY2023Q1	us-gaap	Increase Decrease In Property And Other Taxes Payable IncreaseDecreaseInPropertyAndOtherTaxesPayable	-32728	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	110301	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-274162	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-32318	usd
CY2023Q1	qomo	Cash From Trust Account To Pay Franchise Tax CashFromTrustAccountToPayFranchiseTax	45429	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	45429	usd
CY2022Q1	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	1500	usd
CY2023Q1	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	200000	usd
CY2022Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	18988	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	200000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-20488	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-28733	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-52806	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	196510	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	154565	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	167777	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	101759	usd
CY2023Q1	us-gaap	Income Taxes Paid IncomeTaxesPaid	3802141	usd
CY2023Q1	us-gaap	Business Acquisition Cost Of Acquired Entity Transaction Costs BusinessAcquisitionCostOfAcquiredEntityTransactionCosts	4222030	usd
CY2023Q1	us-gaap	Expense Related To Distribution Or Servicing And Underwriting Fees ExpenseRelatedToDistributionOrServicingAndUnderwritingFees	875000	usd
CY2023Q1	qomo	Deferred Underwriting Fees DeferredUnderwritingFees	2000000	usd
CY2023Q1	qomo	Offering Cost OfferingCost	1347030	usd
CY2022Q4	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	10.15
CY2023Q1	qomo	Maturity Days MaturityDays	P185D
CY2023Q1	qomo	Trust Account Description TrustAccountDescription	Pursuant to Nasdaq listing rules, the Company’s initial Business Combination must occur with one or more target businesses having an aggregate fair market value equal to at least 80% of the value of the funds in the Trust account (excluding any deferred underwriting discounts and commissions and taxes payable on the income earned on the Trust Account), which the Company refers to as the 80% test, at the time of the execution of a definitive agreement for its initial Business Combination, although the Company may structure a Business Combination with one or more target businesses whose fair market value significantly exceeds 80% of the trust account balance. If the Company is no longer listed on Nasdaq, it will not be required to satisfy the 80% test.
CY2023Q1	qomo	Financing Receivable Non Accrual To Outstanding Percent FinancingReceivableNonAccrualToOutstandingPercent	0.50	pure
CY2023Q1	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	10.15
CY2023Q1	us-gaap	Asset Acquisition Consideration Transferred Other Assets AssetAcquisitionConsiderationTransferredOtherAssets	5000001	usd
CY2023Q1	us-gaap	Revenue Remaining Performance Obligation Percentage RevenueRemainingPerformanceObligationPercentage	1	pure
CY2023Q1	qomo	Deposit Into Trust Account DepositIntoTrustAccount	174009	usd
CY2023Q1	us-gaap	Stock Issued During Period Shares Other StockIssuedDuringPeriodSharesOther	0.033	shares
CY2023Q1	us-gaap	Net Asset Value Per Share NetAssetValuePerShare	10.15
CY2023Q1	us-gaap	Dividends Payable Amount Per Share DividendsPayableAmountPerShare	10.15
CY2023Q1	us-gaap	Cash Available For Distributions CashAvailableForDistributions	167777	usd
CY2023Q1	qomo	Working Capital WorkingCapital	513957	usd
CY2023Q1	us-gaap	Policy Loans Receivable PolicyLoansReceivable	200000	usd
CY2022Q3	qomo	Effective Income Tax Rate Reconciliation At Federal Excise Tax Percentage EffectiveIncomeTaxRateReconciliationAtFederalExciseTaxPercentage	0.01	pure
CY2022Q3	qomo	Excise Tax Percentage ExciseTaxPercentage	0.01	pure
CY2023Q1	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Use of Estimates</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In preparing these unaudited financial statements in conformity with U.S. GAAP, the Company’s management makes estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported expenses during the reporting period.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p>
CY2023Q1	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	167777	usd
CY2022Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	196510	usd
CY2023Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-1.1022	pure
CY2022Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2023Q1	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2022Q1	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-224171	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-7318	usd
CY2023Q1	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	-3802141	usd
CY2023Q1	us-gaap	Temporary Equity Net Income TemporaryEquityNetIncome	-4026312	usd
CY2022Q1	us-gaap	Temporary Equity Net Income TemporaryEquityNetIncome	-7318	usd
CY2023Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Concentration of Credit Risk</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage of $250,000. As of March 31, 2023, the Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2023Q1	us-gaap	Federal Deposit Insurance Corporation Premium Expense FederalDepositInsuranceCorporationPremiumExpense	250000	usd
CY2023Q1	qomo	Temporary Equity Accretion To Redemption Value Adjustment1 TemporaryEquityAccretionToRedemptionValueAdjustment1	7211781	usd
CY2022	qomo	Gross Proceeds1 GrossProceeds1	-52730000	usd
CY2022	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	3532910	usd
CY2022	us-gaap	Proceeds From Other Equity ProceedsFromOtherEquity	1845550	usd
CY2022	qomo	Allocation Of Offering Costs Related To Redeemable Shares AllocationOfOfferingCostsRelatedToRedeemableShares	3932347	usd
CY2022	qomo	Accretion Of Carrying Value To Redemption Value One AccretionOfCarryingValueToRedemptionValueOne	3409640	usd
CY2022Q4	us-gaap	Temporary Equity Aggregate Amount Of Redemption Requirement TemporaryEquityAggregateAmountOfRedemptionRequirement	46828833	usd
CY2023Q1	qomo	Accretion Of Carrying Value To Redemption Value One AccretionOfCarryingValueToRedemptionValueOne	3802141	usd
CY2023Q1	us-gaap	Temporary Equity Aggregate Amount Of Redemption Requirement TemporaryEquityAggregateAmountOfRedemptionRequirement	50630974	usd
CY2022Q4	qomo	Sale Of Stock Number Of Shares Issued In Transactions SaleOfStockNumberOfSharesIssuedInTransactions	5000000	shares
CY2022Q4	qomo	Share Per Unit SharePerUnit	10
CY2022Q4	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	50000000	usd
CY2022Q4	us-gaap	Option Indexed To Issuers Equity Shares OptionIndexedToIssuersEquityShares	750000	shares
CY2023Q1	qomo	Initial Public Offering Description InitialPublicOfferingDescription	Each Public Unit consists of one share of common stock (“Public Share”), one right (“Public Right”) and one redeemable warrant (“Public Warrant”). Each Public Right will convert into one-tenth (1/10) of one share of common stock upon the consummation of a Business Combination.
CY2023Q1	qomo	Initial Public Offering Expiration InitialPublicOfferingExpiration	P5Y
CY2023Q1	qomo	Public Shares Sold PublicSharesSold	5273000	shares
CY2021	qomo	Initial Stockholders Percentage InitialStockholdersPercentage	0.20	pure
CY2023Q1	qomo	Aggregate Purchase Price AggregatePurchasePrice	2605000	usd
CY2023Q1	us-gaap	Partners Capital Account Units Sold In Private Placement PartnersCapitalAccountUnitsSoldInPrivatePlacement	8873	shares
CY2023Q1	qomo	Private Placement Description PrivatePlacementDescription	Each Private Unit consists of one share of common stock (“Private Share”), one right (“Private Right”) and one redeemable warrant (“Private Warrant”). Each Private Right will convert into one-tenth (1/10) of one share of common stock upon the consummation of a Business Combination.
CY2021Q3	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	1437500	shares
CY2021Q3	qomo	Aggregate Consideration AggregateConsideration	25000	usd
CY2023Q1	qomo	Issued And Outstanding Shares Percentage IssuedAndOutstandingSharesPercentage	0.20	pure
CY2022Q4	qomo	Shares Forfeited SharesForfeited	119250	shares
CY2022Q4	us-gaap	Excess Stock Shares Outstanding ExcessStockSharesOutstanding	1318250	shares
CY2023Q1	qomo	Founder Shares Percentage FounderSharesPercentage	0.50	pure
CY2021Q3	qomo	Aggregate Amount AggregateAmount	200000	usd
CY2022Q4	qomo	Repaid Outstanding Balance RepaidOutstandingBalance	200000	usd
CY2022Q4	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	155025	usd
CY2023Q1	us-gaap	Policy Loans Receivable PolicyLoansReceivable	200000	usd
CY2023Q1	qomo	Outstanding Promissory Note OutstandingPromissoryNote	355025	usd
CY2022	qomo	Outstanding Promissory Note OutstandingPromissoryNote	155025	usd
CY2023Q1	us-gaap	Convertible Debt ConvertibleDebt	1500000	usd
CY2023Q1	us-gaap	Preferred Stock Convertible Conversion Price PreferredStockConvertibleConversionPrice	10
CY2023Q1	us-gaap	Payments For Rent PaymentsForRent	10000	usd
CY2023Q1	us-gaap	Interest Costs Incurred InterestCostsIncurred	30000	usd
CY2023Q1	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent	30000	usd
CY2023Q1	qomo	Deferred Underwriting Discount Percentage DeferredUnderwritingDiscountPercentage	0.0175	pure
CY2023Q1	qomo	Deferred Fee Percentage DeferredFeePercentage	0.04	pure
CY2023Q1	qomo	Gross Proceeds GrossProceeds	2109200	usd
CY2023Q1	us-gaap	Shares Issued SharesIssued	16000000	shares
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Common Stock Voting Rights CommonStockVotingRights	one
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1437500	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1437500	shares
CY2022Q4	us-gaap	Stock Issued During Period Shares Share Based Compensation Forfeited StockIssuedDuringPeriodSharesShareBasedCompensationForfeited	119250	shares
CY2022Q4	us-gaap	Excess Stock Shares Issued ExcessStockSharesIssued	1662623	shares
CY2022Q4	us-gaap	Excess Stock Shares Outstanding ExcessStockSharesOutstanding	1662623	shares
CY2023Q1	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	5273000	shares
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001894210
CY2023Q1	qomo	Redeem The Outstanding Warrants RedeemTheOutstandingWarrants	●in whole and not in part; ●at a price of $0.01 per warrant; ●upon a minimum of 30 days’ prior written notice of redemption, which the Company refers to as the 30-day redemption period; ●if, and only if, the last reported sale price of the Company’s common stock equals or exceeds $18.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within a 30-trading day period ending on the third trading day prior to the date on which the Company sends the notice of redemption to the to the warrant holders.
CY2023Q1	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	54485634	usd
CY2022Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	53958681	usd
CY2022Q1	us-gaap	Interest Income Securities Other Us Government InterestIncomeSecuritiesOtherUSGovernment		usd
CY2022Q1	qomo	Deferred Tax Provision DeferredTaxProvision		usd
CY2022Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest		usd
CY2022Q1	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits		usd
CY2022Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense		usd
CY2022Q1	us-gaap	Increase Decrease In Property And Other Taxes Payable IncreaseDecreaseInPropertyAndOtherTaxesPayable		usd
CY2022Q1	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable		usd
CY2022Q1	qomo	Cash From Trust Account To Pay Franchise Tax CashFromTrustAccountToPayFranchiseTax		usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities		usd
CY2023Q1	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt		usd
CY2022Q1	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt		usd
CY2023Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts		usd
CY2022Q1	us-gaap	Income Taxes Paid IncomeTaxesPaid		usd
CY2022Q1	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment		usd
CY2022Q1	us-gaap	Interest Costs Incurred InterestCostsIncurred		usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent		usd
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31

Files In Submission

Name	View Source	Status
FilingSummary.xml	Edgar Link	unprocessable
0001213900-23-038897-index-headers.html	Edgar Link	pending
0001213900-23-038897-index.html	Edgar Link	pending
0001213900-23-038897.txt	Edgar Link	pending
0001213900-23-038897-xbrl.zip	Edgar Link	pending
f10q0323ex31-1_qomolangma.htm	Edgar Link	pending
f10q0323ex31-2_qomolangma.htm	Edgar Link	pending
f10q0323ex32-1_qomolangma.htm	Edgar Link	pending
f10q0323ex32-2_qomolangma.htm	Edgar Link	pending
f10q0323_qomolangma.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
qomo-20230331.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
qomo-20230331_cal.xml	Edgar Link	unprocessable
qomo-20230331_def.xml	Edgar Link	unprocessable
qomo-20230331_lab.xml	Edgar Link	unprocessable
qomo-20230331_pre.xml	Edgar Link	unprocessable
f10q0323_qomolangma_htm.xml	Edgar Link	completed
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

Qomolangma Acquisition Corp.

2023 Q2 Form 10-Q Financial Statement

#000121390023038897 Filed on May 12, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission